Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 19, 2019 (7 years ago)

Ropivicaine 0.2%

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

ROPIVICAINE 0.2%, INJ SOLN, 550 ML ON-Q PUMP. RXQ Compounding, 340 West State Street, Unit 9, Athens, OH 45701. NDC: 70731-0238-55

Affected NDC 70731-0238-55

Compare with the code on your package — it is the most precise check available.

Recalling firm
RXQ Compounding LLC
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-1702-2019 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other recalls by RXQ Compounding LLC

All 2019 recalls

Other sterility / contamination recalls from 2019

All sterility / contamination recalls